{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277136","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.589776+00:00","generated_at":"2026-06-08T04:14:45.192981+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives","bullets":["Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.","License and service revenue negative $0.1M; gross royalties $1.2M for quarter.","Operating expenses fell 88.2% to $1.7M on transition to royalty-based model.","Board evaluating strategic alternatives including M&A, sale, or other transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277136","json":"https://secwatch.observer/filing/0001193125-23-277136.json","markdown":"https://secwatch.observer/filing/0001193125-23-277136.md","text":"https://secwatch.observer/filing/0001193125-23-277136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/0001193125-23-277136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/d309650d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:14:45.192981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36a7675512db63e88e41a5a9b387d7d021f9a0fc","claim":"TherapeuticsMD, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di, EPS $0.13 per basic and diluted common share.","evidence_excerpt":"TherapeuticsMD Announces Third Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/0001193125-23-277136-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di"},{"label":"EPS","value":"$0.13 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}